Januvia, Onglyza, And Certain Other Diabetes Drugs Linked To Inflammatory Bowel Disease (IBD)

New Study Finds Overall 75% Increase In Risk Of IBD, And Association Peaked Between 3 And 4 Years Of Use   (Posted by Tom Lamb at DrugInjuryWatch.com)   According to an observational study published on March 21, 2018 by The BMJ — formerly known as British Medical Journal — the use of dipeptidyl peptidase-4 (DPP-4) inhibitors for treatment of type 2 diabetes is associated with increased risk for inflammatory bowel disease (IBD). The following diabetes medicines are in the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs: Januvia (sitagliptin)Janumet (sitagliptin / metformin HCl)Janumet XR (sitagliptin / metformin HCl)Tradjenta (linagliptin)Jentadueto (linagliptin / metformin HCl)Glyxambi (empagliflozin / linagliptin)Onglyza (saxagliptin)Kombiglyze XR (saxagliptin and metformin)Qtern (dapagliflozin and saxagliptin)Nesina (alogliptin)Kazano (alogliptin and metformin)Oseni (alogliptin and pioglitazone) From the Discussion part of this March 2018 BMJ article,…

Read more detail on Recent Health Care Law posts –

This entry was posted in Health Law and tagged , , , , , , , , . Bookmark the permalink.

Leave a Reply